Literature DB >> 15471361

Increased expression of caspase-1 and interleukin-18 in peripheral blood mononuclear cells in patients with multiple sclerosis.

Wen-Xin Huang1, Ping Huang, Jan Hillert.   

Abstract

Multiple sclerosis (MS) is supposedly a T-cell mediated autoimmune disorder of the central nervous system. Cytokines and other molecules involved in the regulation of apoptosis are thought to be of importance for the pathogenesis of MS. In this study, the mRNA levels of interleukin 18 (IL-18), IL-1beta and their processing enzyme caspase-1 were quantified by a competitive RT-PCR method in unstimulated peripheral blood mononuclear cells (PBMCs) in MS patients never treated with disease modifying drugs. Western blot was used to support the expression pattern at the protein level. We found that the expression of caspase-1 and IL-18 was significantly increased in MS patients compared with healthy controls. Analysis of clinical subgroups revealed that caspase-1 was increased in all subgroups, whereas IL-18 was upregulated in chronic progression (P=0.001) and relapsing MS patients in remission (P=0.002) but not significantly during relapses (P=0.12). mRNA levels of IL-1beta were not significantly altered in MS except for a possible decrease in chronic progression (P=0.03). An increased IL-18 expression, potentially augmented at the mature protein level, may indicate a pathway worth considering in future therapeutic strategies in MS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15471361     DOI: 10.1191/1352458504ms1071oa

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  51 in total

Review 1.  Complementing the inflammasome.

Authors:  Martha Triantafilou; Timothy R Hughes; Bryan Paul Morgan; Kathy Triantafilou
Journal:  Immunology       Date:  2016-02       Impact factor: 7.397

Review 2.  Deregulated inflammasome signaling in disease.

Authors:  Mohamed Lamkanfi; Lieselotte Vande Walle; Thirumala-Devi Kanneganti
Journal:  Immunol Rev       Date:  2011-09       Impact factor: 12.988

3.  Interferon-β therapy against EAE is effective only when development of the disease depends on the NLRP3 inflammasome.

Authors:  Makoto Inoue; Kristi L Williams; Timothy Oliver; Peter Vandenabeele; Jayant V Rajan; Edward A Miao; Mari L Shinohara
Journal:  Sci Signal       Date:  2012-05-22       Impact factor: 8.192

4.  NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses.

Authors:  Denis Gris; Zhengmao Ye; Heather A Iocca; Haitao Wen; Robin R Craven; Pavel Gris; Max Huang; Monika Schneider; Stephen D Miller; Jenny P-Y Ting
Journal:  J Immunol       Date:  2010-06-23       Impact factor: 5.422

5.  Quantitative differences in the immunomodulatory effects of Rebif and Avonex in IFN-β 1a treated multiple sclerosis patients.

Authors:  George P Christophi; Jennifer A Christophi; Ross C Gruber; Cornelia Mihai; Luis J Mejico; Paul T Massa; Burk Jubelt
Journal:  J Neurol Sci       Date:  2011-06-11       Impact factor: 3.181

Review 6.  Inflammasomes and autoimmunity.

Authors:  Patrick J Shaw; Michael F McDermott; Thirumala-Devi Kanneganti
Journal:  Trends Mol Med       Date:  2010-12-14       Impact factor: 11.951

Review 7.  APC-derived cytokines and T cell polarization in autoimmune inflammation.

Authors:  Ilona Gutcher; Burkhard Becher
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 8.  Interleukin 18 in the CNS.

Authors:  Silvia Alboni; Davide Cervia; Shuei Sugama; Bruno Conti
Journal:  J Neuroinflammation       Date:  2010-01-29       Impact factor: 8.322

Review 9.  Close Encounters of the First Kind: Innate Sensors and Multiple Sclerosis.

Authors:  Lidia Fernández-Paredes; Rebeca Pérez de Diego; Clara de Andrés; Silvia Sánchez-Ramón
Journal:  Mol Neurobiol       Date:  2016-01-05       Impact factor: 5.590

10.  Macrophages of multiple sclerosis patients display deficient SHP-1 expression and enhanced inflammatory phenotype.

Authors:  George P Christophi; Michael Panos; Chad A Hudson; Rebecca L Christophi; Ross C Gruber; Akos T Mersich; Scott D Blystone; Burk Jubelt; Paul T Massa
Journal:  Lab Invest       Date:  2009-04-27       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.